

Subcutaneous application of gammanorm®

Submission date 30/05/2014	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 23/09/2014	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 30/09/2014	Condition category Haematological Disorders	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

An antibody is a protein made by the immune system that recognises harmful substances in the body, such as bacteria and viruses, and neutralises them. Gammanorm® is a human immunoglobulin medicine that contains a number of antibodies and is given as an injection to treat people that have immune systems that produce few antibodies; these include patients with congenital or acquired antibody deficiencies. We want to find out more about the daily routine use of gammanorm® and get information about patient satisfaction and health-related quality of life during therapy.

Who can participate?

Patients of any age and gender that are treated with gammanorm®.

What does the study involve?

Doctors that have patients being treated with gammanorm® document, or record, information about those patients. This includes gathering data about how the patient takes their medicine, the disease they are suffering from, their age, gender, weight, any other medicine they are taking or any other illnesses that they have. No special investigations or procedures need to be done and it does not interfere with the patient's usual treatment as prescribed by the doctor. In order to get information about the health-related quality of life, patients are asked by their doctors to fill in a questionnaire at the beginning of the study and then every six months for up to 2 years.

What are the possible benefits and risks of participating?

The data will help to build up detailed knowledge about the subcutaneous route (that is, injection) of immunoglobulin treatment, especially regarding the patient's satisfaction and health-related quality of life. Gammanorm® is a registered product, the possible side-effects are described in the package insert.

Where is the study run from?

The trial takes place in about 30 study centres in Germany.

When is study starting and how long is it expected to run for?

June 2014 to May 2018

Who is funding the study?
Octapharma GmbH (Germany)

Who is the main contact?
Dr. Anette Debes
anette.debes@octapharma.de

Contact information

Type(s)
Scientific

Contact name
Dr Axel Jansink

Contact details
Elisabeth-Selbert-Str. 11
Langenfeld
Germany
40764

Additional identifiers

Protocol serial number
GAN-04

Study information

Scientific Title
Non-interventional study on the subcutaneous application of gammanorm®

Study objectives
Home-based subcutaneous treatment with gammanorm® improves patient's satisfaction and quality of life.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at the time of registration

Primary study design
Observational

Study design
Non-interventional, prospective, multi-centre, observational study

Study type(s)
Treatment

Health condition(s) or problem(s) studied

Primary immunodeficiency syndromes/severe secondary hypogammaglobulinaemia

Interventions

Treatment with gammanorm in routine clinical use will be documented. This includes data about the patient's disease, age, gender, weight, concomitant medication or illness and information about the application. If available, laboratory data about the efficacy of treatment should also be documented. Information about quality of life will be documented at the beginning and every six months. Each patient can be documented for a maximum of 2 years. No special or additional investigations must be initiated for the purpose of this non-interventional study.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Information about the treatment with gammanorm® in home therapy and the health-related quality of life will be collected by using CRFs and appropriate questionnaires (SF-36 and CHQ-PF50).

Key secondary outcome(s)

Efficacy of treatment will be measured by evaluating laboratory data, if available.

Completion date

31/05/2018

Eligibility**Key inclusion criteria**

Patients of any gender and age, who receive treatment with gammanorm®

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Other

Sex

All

Key exclusion criteria

Hypersensitivity to any of the components

Date of first enrolment

01/06/2014

Date of final enrolment

31/05/2018

Locations

Countries of recruitment

Germany

Study participating centre

Elisabeth-Selbert-Str. 11

Langenfeld

Germany

40764

Sponsor information

Organisation

Octapharma GmbH (Germany)

ROR

<https://ror.org/002k5fe57>

Funder(s)

Funder type

Industry

Funder Name

Octapharma GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration